Recent studies in metastatic castration-sensitive prostate cancer have highlighted the potential benefits of giving systemic treatment with androgen deprivation earlier. Although such an approach might significantly improve survival, data showing such an effect may not be available for many years after trial initiation, and intermediate end points might facilitate future studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yu, E. Y. et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 33, 1601–1608 (2015).
Wu, J. D. et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 99, 392–401 (2006).
Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).
Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial [abstract LBA2]. J. Clin. Oncol. 32, 5s (2014).
Even-Sapir, E. et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J. Nucl. Med. 47, 287–297 (2006).
Poulsen, M. H. et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int. 114, 818–823 (2014).
Afshar-Oromieh, A. et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 11–20 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Madan, R., Dahut, W. Charting a course in metastatic castration-sensitive prostate cancer. Nat Rev Urol 12, 368–369 (2015). https://doi.org/10.1038/nrurol.2015.144
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.144
